ADQ, headquartered in Abu Dhabi, has consolidated its holdings in the life sciences sector to establish Arcera, a new holding company focused on enhancing human life quality and longevity.
Arcera, based in Abu Dhabi, now oversees ADQ’s interests in Acino, a Swiss pharmaceutical company, Birgi Mefar Group (BMG) specializing in sterile injectables and glass packaging from Turkey, and Egypt’s Amoun pharmaceutical company.
With a portfolio comprising 2,000 branded medications across various therapeutic areas such as neurology, gastroenterology, cardiovascular, pain relief, rheumatology, and anti-infectives, Arcera operates manufacturing and packaging facilities across seven locations globally, including the UAE, Switzerland, Ukraine, Estonia, South Africa, Turkey, and Egypt.
ADQ aims to double Arcera’s revenue over the next five years through strategic acquisitions and partnerships, aligning with its commitment to innovation, globalization, and digitization in the life sciences industry.
Hamad Al Hammadi, ADQ’s deputy chief executive, sees Arcera as a significant contributor to Abu Dhabi’s life sciences sector and its economic diversification goals.
As part of the UAE’s strategy to bolster non-oil industries, particularly in innovation, Arcera’s establishment aligns with the country’s goal of reducing pharmaceutical imports and developing local manufacturing capabilities.
ADQ’s broader healthcare and life sciences portfolio expansion includes acquisitions of Acino, Amoun, BMG, and a minority stake in India’s Biocon Biologics, specializing in biosimilars.
Arcera plans to collaborate with academic institutions and pharmaceutical companies to advance healthcare solutions addressing regional and global needs.
Isabel Afonso, Arcera’s CEO, envisions the company as a leading global player in life sciences, driving advancements that promote longer, healthier lives while creating value.
